PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24478822-1	2012	PROBLEM STATEMENT: Diphenylhydantoin (phenytoin) is an antiepileptic drug that generates hyperplasia in some tissue by stimulating Epidermal Growth Factor (EGFR) and Platelet-Derived Growth Factor beta (PDGFR-beta) receptors and by increasing serum levels of basic fibroblast growth factor (bFGF, FGF2 or FGF-beta).	Phenytoin	19-36	epidermal growth factor	Homo sapiens	131-154	
9385775-0	1997	Fibroblasts derived from tissue explants of dilantin-induced gingival hyperplasia and idiopathic gingival fibromatosis show distinct disparity in proliferative responsiveness to epidermal growth factor.	Phenytoin	44-52	epidermal growth factor	Homo sapiens	178-201	
9379324-12	1997	EGF and IL-1 present in inflammatory exudate may have implications on phenytoin-induced overgrowth via the steroid metabolic pathway.	Phenytoin	70-79	epidermal growth factor	Homo sapiens	0-3	
2139117-4	1990	The steady-state level of EGF-r mRNA increased significantly (p less than 0.001) in the cultured fibroblasts derived from the non-responder but decreased (p less than 0.05) in the responder patient following PHT therapy.	Phenytoin	208-211	epidermal growth factor	Homo sapiens	26-29	
2139117-6	1990	The study indicates that PHT medication results in a down-regulation of EGF receptor metabolism in fibroblasts derived from a responder patient, whereas in the non-responder patient EGF receptor metabolism is up-regulated.	Phenytoin	25-28	epidermal growth factor	Homo sapiens	72-75	
24478822-1	2012	PROBLEM STATEMENT: Diphenylhydantoin (phenytoin) is an antiepileptic drug that generates hyperplasia in some tissue by stimulating Epidermal Growth Factor (EGFR) and Platelet-Derived Growth Factor beta (PDGFR-beta) receptors and by increasing serum levels of basic fibroblast growth factor (bFGF, FGF2 or FGF-beta).	Phenytoin	19-36	epidermal growth factor	Homo sapiens	156-160